for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kindred Biosciences Inc

KIN.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Kindred Biosciences Receives FDA Approval Of Zimeta For The Control Of Pyrexia In Horses

Nov 25 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF ZIMETA™ (DIPYRONE INJECTION) FOR THE CONTROL OF PYREXIA IN HORSES.KINDRED BIOSCIENCES - U.S. FOOD AND DRUG ADMINISTRATION'S CENTER FOR VETERINARY MEDICINE APPROVED ZIMETA FOR CONTROL OF PYREXIA IN HORSES.

Kindred Biosciences Posts Q3 Loss Per Share of $0.39

Nov 12 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.39.Q3 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, KINDREDBIO HAD $87.6 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.

Kindred Biosciences Says Positive Opinion From CVMP In The EU For Mirataz For Cats Experiencing Poor Appetite And Weight Loss

Oct 10 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES POSITIVE OPINION FROM CVMP IN THE EUROPEAN UNION FOR MIRATAZ® (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR CATS EXPERIENCING POOR APPETITE AND WEIGHT LOSS.KINDRED BIOSCIENCES INC - A MARKETING AUTHORIZATION DECISION FROM EUROPEAN COMMISSION IS ANTICIPATED WITHIN APPROXIMATELY TWO MONTHS.KINDRED BIOSCIENCES INC - IN CANADA, VALIDATION OF CANADIAN SUBMISSION WILL BE COMPLETE IN NEXT 30 TO 45 DAYS AND ONCE ACCEPTED FOR REVIEW.KINDRED BIOSCIENCES INC - CVMP'S POSITIVE OPINION IS BASED ON RESULTS FROM BOTH CLINICAL AND NON-CLINICAL STUDIES.

Kindred Biosciences Awarded Contract By The National Cancer Institute In Support Of The Prevent Cancer Program

Sept 10 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES AWARDED A CONTRACT BY THE NATIONAL CANCER INSTITUTE IN SUPPORT OF THE PREVENT CANCER PROGRAM.KINDRED BIOSCIENCES - TASK ORDERS AWARDED TO KINDREDBIO ARE EXPECTED TO BE CONDUCTED AT COMPANY'S CGMP MANUFACTURING FACILITY IN BURLINGAME, CA.KINDRED BIOSCIENCES INC - A MAXIMUM AMOUNT OF $49.95 MILLION WILL BE SHARED ACROSS THREE CONTRACT POOLS, ONE OF WHICH IS CGMP MANUFACTURING POOL.KINDRED BIOSCIENCES INC - WITHIN CGMP POOL, KINDREDBIO IS ONE OF THREE CONTRACTORS SELECTED FOR AWARD.KINDRED BIOSCIENCES INC - CONTRACT TERM IS FOUR YEARS, WITH SPECIFIC AMOUNTS BASED ON INDIVIDUAL TASK ORDER AWARDS YET TO BE DETERMINED.

Kindred Biosciences Reports Q2 Loss Per Share $0.37

Aug 1 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND UNVEILS POSITIVE RESULTS FROM PILOT EFFICACY STUDY OF PARVOVIRUS MONOCLONAL ANTIBODY.Q2 LOSS PER SHARE $0.37.Q2 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.TARGETING APPROVAL OF PARVOVIRUS MONOCLONAL ANTIBODY PRODUCT CANDIDATE BY LATE 2020, OR EARLY 2021.RECORDED $1.2 MILLION IN NET PRODUCT REVENUES FOR MIRATAZ FOR Q2.

Kindred Biosciences Says Notified By Contract Manufacturer That FDA Has Follow Up Questions Following March Inspection

May 16 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES-NOTIFIED BY CONTRACT MANUFACTURER OF API DIPYRONE THAT FDA CENTER FOR VETERINARY MEDICINE HAS FOLLOW UP QUESTIONS, FOLLOWING MARCH INSPECTION.KINDRED - ONCE RESPONSES ARE PROVIDED BY API MANUFACTURER, CO INTENDS TO REACTIVATE NADA FOR DIPYRONE INJECTION FOR CONTROL OF PYREXIA IN HORSES.KINDRED BIOSCIENCES INC - FDA HAS GRANTED A SHORTENED TIMELINE OF 135 DAYS FOR REVIEW OF NADA.KINDRED BIOSCIENCES INC - WILL PROVIDE AN UPDATE ON TIMING OF DIPYRONE INJECTION'S EXPECTED APPROVAL DURING ITS Q2 2019 RESULTS..

Kindred Biosciences Q1 Loss Per Share $0.42

May 9 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.42.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.KINDRED BIOSCIENCES - BELIEVES EXISTING CASH, CASH EQUIVALENTS, OTHERS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH EARLY 2021..

Kindred Biosciences Announces Fourth Quarter And Full Year 2018 Financial Results

March 6 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.QTRLY NET PRODUCT REVENUES $1.3 MILLION VERSUS NO PRODUCT REVENUES FOR THE SAME PERIOD LAST YEAR.

Kindred Biosciences Says Public Offering Of 4.22 Mln Common Shares Priced At $9.50/Share

Jan 18 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.22 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.

Kindred Biosciences Inc Says Expects To Record About $2.0 Mln In Net Product Revenues For Year Ended December 31, 2018

Jan 17 (Reuters) - Kindred Biosciences Inc <KIN.O>::KINDRED BIOSCIENCES INC - EXPECTS TO RECORD ABOUT $2.0 MILLION IN NET PRODUCT REVENUES FOR YEAR ENDED DECEMBER 31, 2018.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up